Industry News

Pharmaceutical Industry News

Shortly after locking down its…

May 12th, 2026|Fierce Pharma|

Shortly after locking down its $4.8 billion deal for rare disease compatriot Amicus Therapeutics, BioMarin is consolidating the workforce tied to the acquired company’s headquarters in New Jersey

Marty Makary, M.D., is resigning…

May 12th, 2026|Fierce Pharma|

Marty Makary, M.D., is resigning as FDA commissioner Tuesday, ending a brief but tumultuous tenure marked by mounting criticism from all sides, according to reports.

Eli Lilly has paused an obesity…

May 12th, 2026|Fierce Pharma|

Eli Lilly has paused an obesity awareness campaign in India in response to a regulatory notice regarding advertising rules for prescription medicines, Reuters reports.

Alkermes has chalked up a quick…

May 12th, 2026|Fierce Pharma|

Alkermes has chalked up a quick clinical win from its $2.37 billion acquisition of Avadel, reporting Tuesday that a phase 3 study of the sodium oxybate drug Lumryz met all primary and key secondary endpoints

The deal includes up to $320…

May 12th, 2026|Fierce Pharma|

The deal includes up to $320 million in future milestone payments plus tiered royalties on Veppanu sales, which will be split evenly between Arvinas and Pfizer.

After staving off significant…

May 12th, 2026|Fierce Pharma|

After staving off significant sales declines for Eylea, Bayer is getting hit with full force by biosimilar competition for the eye disease treatment, which saw a 24% sales decline in the first quarter.

Amid apparent overtures from the…

May 12th, 2026|Fierce Pharma|

Amid apparent overtures from the Trump administration to curb public vaccine criticism ahead of the midterms this fall, the secretary of the Department of Health and Human Services is allegedly continuing his crusade in the

After positive momentum on the…

May 12th, 2026|Fierce Pharma|

After positive momentum on the plan in late 2025, European Union lawmakers have taken a critical step toward implementing a new framework for the bloc focused on boosting supplies of critical medicines and navigating potential

As Bicara Therapeutics lines up…

May 12th, 2026|Fierce Pharma|

As Bicara Therapeutics lines up for a potential accelerated cancer drug approval next year, the biotech has appointed Chris Sarchi as its chief commercial officer.

CSL has slashed its revenue…

May 11th, 2026|Fierce Pharma|

CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the Australian company’s financial distress since its 2022 acquisition of Vifor Pharma for $11.7 billion.

With the program’s seventh…

May 11th, 2026|Fierce Pharma|

With the program’s seventh approval in the books, the FDA is illustrating just how speedy it can be with drug reviews that fall under its U.S. national priority pilot.

Daiichi Sankyo aims to transform…

May 11th, 2026|Fierce Pharma|

Daiichi Sankyo aims to transform its antibody-drug conjugate leadership into a top global oncology standing. In a new five-year business plan unveiled Monday, the Japanese pharma outlined a roadmap to become a global top five

OVID Health has hired former…

May 11th, 2026|Fierce Pharma|

OVID Health has hired former Edelman global public health lead Davide Scalenghe to expand the agency’s international strategy and partnerships work.

Flashy three-pointers; top…

May 11th, 2026|Fierce Pharma|

Flashy three-pointers; top athletes playing under the lights; cameras focusing in on our celebrity making a game-winning shot—all elements you’d typically associate with a Big Pharma ad featuring a major athletic celebrity. Not for Eli